SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Canadian Agency Recommends Reimbursement for Lilly’s Kisunla

Canada’s drug reimbursement body issued a positive recommendation for Kisunla (donanemab) for early Alzheimer’s disease.

LLY

Related stories